Jiuyuan Gene (02566) Secures NMPA IND Approval for SIRPα-Targeting JY47 Injection in MASH with Liver Fibrosis

Bulletin Express

Mar 17

Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (Jiuyuan Gene, 02566) disclosed that China’s National Medical Products Administration (NMPA) has cleared the Company’s investigational new drug (IND) application for JY47 Injection, authorising the commencement of clinical trials in patients with metabolic dysfunction-associated steatohepatitis (MASH) accompanied by liver fibrosis.

JY47 is a monoclonal antibody that antagonises signal-regulatory protein-alpha (SIRPα). The CD47-SIRPα pathway is recognised for its inhibitory role in immune regulation; blocking SIRPα is expected to restore immune cell activity, improve tissue micro-environment, and help re-establish metabolic homeostasis. Pre-clinical studies showed encouraging effects in both in-vitro organoid and in-vivo disease models of MASH.

The Board emphasised that JY47 is independently developed within Jiuyuan Gene’s biologics pipeline, illustrating progress in the Group’s R&D strategy. No financial figures or projected timelines were provided in the announcement.

Shareholders and potential investors are advised to exercise caution when dealing in the Company’s shares.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/1181125783"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1181125783\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1181125783?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-17 17:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1181125783","market":"hk","top_or_hot":-1,"title":"Jiuyuan Gene (02566) Secures NMPA IND Approval for SIRPα-Targeting JY47 Injection in MASH with Liver Fibrosis","media":"Bulletin Express","content":"<p>Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (Jiuyuan Gene, 02566) disclosed that China’s National Medical Products Administration (NMPA) has cleared the Company’s investigational new drug (IND) application for JY47 Injection, authorising the commencement of clinical trials in patients with metabolic dysfunction-associated steatohepatitis (MASH) accompanied by liver fibrosis.</p>\n<p>JY47 is a monoclonal antibody that antagonises signal-regulatory protein-alpha (SIRPα). The CD47-SIRPα pathway is recognised for its inhibitory role in immune regulation; blocking SIRPα is expected to restore immune cell activity, improve tissue micro-environment, and help re-establish metabolic homeostasis. Pre-clinical studies showed encouraging effects in both in-vitro organoid and in-vivo disease models of MASH.</p>\n<p>The Board emphasised that JY47 is independently developed within Jiuyuan Gene’s biologics pipeline, illustrating progress in the Group’s R&D strategy. No financial figures or projected timelines were provided in the announcement.</p>\n<p>Shareholders and potential investors are advised to exercise caution when dealing in the Company’s shares.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Jiuyuan Gene (02566) Secures NMPA IND Approval for SIRPα-Targeting JY47 Injection in MASH with Liver Fibrosis</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJiuyuan Gene (02566) Secures NMPA IND Approval for SIRPα-Targeting JY47 Injection in MASH with Liver Fibrosis\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-03-17 17:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (Jiuyuan Gene, 02566) disclosed that China’s National Medical Products Administration (NMPA) has cleared the Company’s investigational new drug (IND) application for JY47 Injection, authorising the commencement of clinical trials in patients with metabolic dysfunction-associated steatohepatitis (MASH) accompanied by liver fibrosis.</p>\n<p>JY47 is a monoclonal antibody that antagonises signal-regulatory protein-alpha (SIRPα). The CD47-SIRPα pathway is recognised for its inhibitory role in immune regulation; blocking SIRPα is expected to restore immune cell activity, improve tissue micro-environment, and help re-establish metabolic homeostasis. Pre-clinical studies showed encouraging effects in both in-vitro organoid and in-vivo disease models of MASH.</p>\n<p>The Board emphasised that JY47 is independently developed within Jiuyuan Gene’s biologics pipeline, illustrating progress in the Group’s R&D strategy. No financial figures or projected timelines were provided in the announcement.</p>\n<p>Shareholders and potential investors are advised to exercise caution when dealing in the Company’s shares.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02566","symbol_name":"九源基因","start_time":0,"source_url":"","article_id":"1181125783","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1181125783","pubTimestamp":1773739385,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (Jiuyuan Gene, 02566) disclosed that China’s National Medical Products Administration (NMPA) has cleared the Company’s investigational new drug...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02566":"九源基因"},"translate_title":"九原基因(02566)靶向SIRP α的JY47注射液治疗肝纤维化MASH获得NMPA IND批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02566":1},"content_text":"Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (Jiuyuan Gene, 02566) disclosed that China’s National Medical Products Administration (NMPA) has cleared the Company’s investigational new drug (IND) application for JY47 Injection, authorising the commencement of clinical trials in patients with metabolic dysfunction-associated steatohepatitis (MASH) accompanied by liver fibrosis.\nJY47 is a monoclonal antibody that antagonises signal-regulatory protein-alpha (SIRPα). The CD47-SIRPα pathway is recognised for its inhibitory role in immune regulation; blocking SIRPα is expected to restore immune cell activity, improve tissue micro-environment, and help re-establish metabolic homeostasis. Pre-clinical studies showed encouraging effects in both in-vitro organoid and in-vivo disease models of MASH.\nThe Board emphasised that JY47 is independently developed within Jiuyuan Gene’s biologics pipeline, illustrating progress in the Group’s R&D strategy. No financial figures or projected timelines were provided in the announcement.\nShareholders and potential investors are advised to exercise caution when dealing in the Company’s shares.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}